Preview Content

In our Digital Dialogue, we explored how digital innovation is reshaping the clinical trials landscape, with a focus on enabling more inclusive, efficient, and patient-centred approaches.

We were delighted to be joined by Matthew Bonam and Elaine Harrop for an engaging conversation on how digital innovation is transforming the way clinical trials are designed and delivered.

Speakers & Presentations

• Overview of Evolving Clinical Trials Landscape and the Transformative Role of New and Emerging Technologies – Matthew Bonam, VP Digital Health Strategy, Evinova

• Case Study: Reimagining Clinical Trials Operations in the Digital Era – Elaine Harrop, VP Clinical Operations, Respiratory & Immunology at AstraZeneca

Our second Digital Dialogue examined the current state of DHT use in clinical trials, with a focus on addressing the practical, regulatory, and scientific barriers limiting broader uptake. 

We were joined by five leaders in the Clinical space who highlighted the role of digital health technologies (DHTs), with particular emphasis on cross-sector collaborations driving real-world clinical trial impact.

Speakers

• Jarjieh Fang, Director, HVE, Patient-Centered Outcomes Assessment, Pfizer
• Jay Trudeau, Senior Director, Eli Lilly & Co
• Marie McCarthy, Digital Endpoint Lead Director, Novartis
• Farrell Healion, Founder and Principal Consultant, OptiTrial
• Scottie Kern, Executive Director, eCOA Consortium, C-Path